CYP2D6 genotypes in Spanish women with breast cancer

被引：26

作者：

Ladona, MG

Abildua, RE

Ladero, JM

Roman, JM

Plaza, MA

Agundez, JAG

Munoz, JJ

Benitez, J

机构：

[1] UNIV COMPLUTENSE MADRID, DEPT PHARMACOL, MADRID, SPAIN

[2] UNIV EXTREMADURA, DEPT PHARMACOL, BADAJOZ, SPAIN

[3] SAN CARLOS UNIV HOSP, SERV GASTROENTEROL, MADRID, SPAIN

[4] SAN CARLOS UNIV HOSP, SERV OBSTET & GYNAECOL, BREAST UNIT, MADRID, SPAIN

来源：

CANCER LETTERS | 1996年 / 99卷 / 01期

关键词：

CYP2D6; P4502D6; breast cancer; debrisoquine; polymorphism;

D O I：

10.1016/0304-3835(95)04033-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Wild type and three mutated alleles of the polymorphic CYP2D6 gene were studied in genomic DNA samples from 187 women with breast carcinoma and 151 healthy women by a mutation-specific polymerase chain reaction. The prevalence of the enzyme-inactivating CYP2D6(B) allele was higher among patients (18.2%) than in controls (11.6%; OR = 1.7; 95% c.i. = 1.14-3.13; P = 0.018). This excess was more marked in postmenopausal patients (19.8%, P = 0.0086) and in patients with non-ductal infiltrating carcinomas (25.8%, P = 0.003). The percentage of carriers of only one active gene (heterozygote extensive metabolizers) was higher in patients (31% vs. 19.9%; OR = 1.81; 95% c.i. = 1.06-3.11; P = 0.02). The CYP2D6(B)-carrier state may be related to a greater risk of breast cancer in women.

引用

页码：23 / 28

页数：6

共 50 条

[1] Influence of CYP2D6 Polymorphisms on Serum Levels of Tamoxifen Metabolites in Spanish Women with Breast Cancer
Zafra-Ceres, Mercedes
de Haro, Tomas
Farez-Vidal, Esther
Blancas, Isabel
Bandres, Fernando
de Duenas, Eduardo Martinez
Ochoa-Aranda, Enrique
Gomez-Capilla, Jose A.
Gomez-Llorente, Carolina
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2013, 10 (07): : 932 - 937
[2] Polymorphism of the CYP2D6 gene in women with breast cancer treated with tamoxifen
de Vasconcelos-Valenca, R. J.
Melo, M. A.
Lima, E. M.
de Sousa, G. V.
Nazario, A. C.
da Silva, B. B.
EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2016, 37 (05) : 700 - 702
[3] CYP2D6 and ESR genotypes in adjuvant tamoxifen treatment for early breast cancer.
Kim, K.
Jung, K. H.
Ahn, J.
Kim, S.
Kim, H. J.
Ko, B.
Lee, J. W.
Son, B. H.
Ahn, S.
Gong, G.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (27)
[4] Dose adjustment of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients
不详
PHARMACOGENOMICS, 2012, 13 (06) : 647 - 648
[5] Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer
Lim, Hyeong-Seok
Lee, Han Ju
Lee, Keun Seok
Lee, Eun Sook
Jang, In-Jin
Ro, Jungsil
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (25) : 3837 - 3845
[6] CYP2D6 genotypes in a Japanese population:: low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10
Nishida, Y
Fukuda, T
Yamamoto, I
Azuma, J
PHARMACOGENETICS, 2000, 10 (06): : 567 - 570
[7] Impact of CYP2D6 Polymorphisms on the Efficacy of Tamoxifen in Iraqi Women With Breast Cancer
Ali, Sura S. Abid
Sahib, Ahmed S.
Abdulamir, Ahmed S.
Kadhim, Haitham M.
JOURNAL OF CONTEMPORARY MEDICAL SCIENCES, 2023, 9 (06): : 436 - 448
[8] Risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors
Aubert, R. E.
Stanek, E. J.
Yao, J.
Teagarden, J. R.
Subar, M.
Epstein, R. S.
Skaar, T. C.
Desta, Z.
Flockhart, D. A.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (18)
[9] Polymorphism of the CYP2D6 gene in Brazilian women with breast cancer treated with tamoxifen
da Silva, B. B.
de Vasconcelos-Valenca, R. J.
Lopes-Costa, P. V.
Gebrim, L. H.
CANCER RESEARCH, 2013, 73
[10] Contribution of ABCB1 and CYP2D6 Genotypes to the Outcome of Tamoxifen Adjuvant Treatment in Premenopausal Women With Breast Cancer
Argalacsova, S.
Slanar, O.
Vitek, P.
Tesarova, P.
Bakhouche, H.
Drazdakova, M.
Bartosova, O.
Zima, T.
Pertuzelka, L.
PHYSIOLOGICAL RESEARCH, 2015, 64 : S539 - S547

← 1 2 3 4 5 →